- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05260931
Fetal Cardiac Remodeling in Gestational Diabetic Pregnancies at the Moment of Diagnosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
We will recruited patients at the time of 75-g oral glucose tolerance test (OGTT); GDM will be diagnosed at 24-28.6 weeks when one or more of the venous plasma glucose measurements met or exceeded the following thresholds: fasting blood glucose ≥ 92 mg/dL; 1 h plasma glucose level ≥ 180 mg/dL; or 2 h plasma glucose level ≥ 153 mg/dL, as recommended by the International Association of the Diabetes and Pregnancy Study Groups. Consecutive women with singleton pregnancies with negative OGTT findings wil be also recruited during this period.
Maternal Characteristics The baseline variables, including maternal age, height, weight (1st ans 2nd trimester), parity will be collected at the time of the ultrasound examination. Additionally, fasting blood glucose, 1 h plasma glucose level and 2 h plasma glucose level in 75-g OGTT and glycated hemoglobin A1 (HbA1c) will be recorded. Body mass index of all mothers will be calculated.
Ultrasonographic examination using Voluson E6 (GE Medical Systems, Milwaukee, MI, USA) with 2-8 MHz linear curved-array probes, including estimated fetal weight, anomaly scan, and fetal echocardiography. The images will be recorded as clips and anonymized, and all the measurements will be performed offline.
Fetal biometric measurements will be obtained following ISUOG recommendations and fetal weight with Hadlock 4 formula.
Comprehensive two-dimensional, M-mode, and Doppler echocardiographic examination will be performed to rule out cardiac defects, and to evaluate cardiac morphometry and function following standard protocols. Cardiac, thoracic, and ventricular areas and diameters will be measured on 2-dimensional images from an apical or basal four-chamber (4 ChV) view at end diastole. Ventricular sphericity indices calculated by dividing the longitudinal by basal-transverse ventricular diameters. Atrial areas measured at maximum distension at end of systole. Atria and ventricle to-heart ratios will be calculated. Myocardial wall thicknesses measured on M-mode images from a transverse 4 ChV. Ventricular ejection fractions will be obtained from M-mode transverse 4 ChV using the Teichholz's formula. MAPSE/TAPSE will be assessed by M-mode from an apical or basal 4 ChV. Mitral and tricuspid early and late ventricular filling will be obtained by Doppler, and E/A ratios calculated. The left and right myocardial performance indices obtained from Doppler spectrum in a cross-sectional image of the thorax.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Flavio Hernández Castro, MD PhD
- Phone Number: 8112776459
- Email: flaviohernandezc@yahoo.com
Study Locations
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico
- Recruiting
- Hospital Universitario "Dr. Jose E. Gonzalez" UANL
-
Contact:
- Flavio Hernández Castro, PhD
- Phone Number: 8112776459
- Email: flaviohernandezc@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All pregnant women who will undergo 75g OGTT between 24 and 28.6 weeks of gestation will be invited to participate. Before being recruited, the objective of the research will be explained, the confidential nature of the information and informed consent will be requested. Inclusion criteria: singleton spontaneously conceived pregnancy, first trimester ultrasound screening to establish gestational age and first trimester serum glycemia < 92 mg/dL.
Exclusion Criteria:
- Those women with conditions or comorbidities that could induce cardiac remodeling and suboptimal function or could modify fetal growth will be excluded: fetus conceived by ssisted reproductive technology, pregestational diabetes, systemic lupus erythematosus, antiphospholipid antibody syndrome and other thrombophilias, heart disease, chronic pulmonary or renal disease, and thyroid disease. In addition, any hypertensive disease in pregnancy or derived complications (chronic arterial hypertension, gestational hypertension, pre-eclampsia, eclampsia). Patients with exposure to substances that could affect fetal weight will be excluded: teratogens (cyclophosphamide, valproic acid, antithrombotic drugs), tobacco, alcohol, cocaine or coffee consumption of more than 1 cup/day. Finally, women with a history of intrauterine growth restriction (IUGR) and/or preeclampsia in previous pregnancies, high risk of IUGR and/or preeclampsia in the current pregnancy estimated at first trimester screening, mean uterine artery greater than the 95th percentile for gestational age at 24-28.6 weeks, fetal structural defects or markers of aneuploidy on first or second trimester ultrasonography will be also excluded.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Crossover
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Gestational diabetes group
This group will be formed by women with gestational diabetes (GD).
The diagnosis of GD was made when one or more of the venous plasma glucose measurements met or exceeded the following thresholds after a 75 g Oral Glucose Tolerance Test (75 g OGTT): fasting blood glucose ≥ 92 mg/dL, 1 h plasma glucose level ≥ 180 mg/dL or 2 h plasma glucose level ≥ 153 mg/dL, as recommended by the International Association of the Diabetes and Pregnancy Study Groups.
|
Two-dimensional, M mode, and Doppler echocardiographic examination performed to rule out cardiac defects and to evaluate cardiac morphometry and function.
Cardiac, thoracic, and ventricular areas and diameters measured on 2-dimensional images from an apical or basal four-chamber (4 ChV) view at end diastole.
Ventricular sphericity indices calculated by dividing the longitudinal by basal-transverse ventricular diameters.
Atrial areas at maximum distension at end of systole.
Atria and ventricle to-heart ratios calculated.
Myocardial wall thicknesses and ventricular shortening/ejection fractions obtained from M-mode transverse 4 ChV.
MAPSE/TAPSE assessed by M-mode from an apical or basal 4 ChV.
Mitral and tricuspid early and late ventricular filling obtained by Doppler, and E/A ratios calculated.
Left and right myocardial performance indices obtained from Doppler spectrum in a cross-sectional image of the thorax.
|
Control group
This group will be formed by women with normal 75 g OGTT findings.
|
Two-dimensional, M mode, and Doppler echocardiographic examination performed to rule out cardiac defects and to evaluate cardiac morphometry and function.
Cardiac, thoracic, and ventricular areas and diameters measured on 2-dimensional images from an apical or basal four-chamber (4 ChV) view at end diastole.
Ventricular sphericity indices calculated by dividing the longitudinal by basal-transverse ventricular diameters.
Atrial areas at maximum distension at end of systole.
Atria and ventricle to-heart ratios calculated.
Myocardial wall thicknesses and ventricular shortening/ejection fractions obtained from M-mode transverse 4 ChV.
MAPSE/TAPSE assessed by M-mode from an apical or basal 4 ChV.
Mitral and tricuspid early and late ventricular filling obtained by Doppler, and E/A ratios calculated.
Left and right myocardial performance indices obtained from Doppler spectrum in a cross-sectional image of the thorax.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ventricular sphericity indices
Time Frame: 45-60 minutes
|
Left and right Ventricular sphericity indices will be calculated by dividing the longitudinal by basal-transverse ventricular diameters on 2-dimensional images from an apical or basal four-chamber (4 ChV) view at end diastole.
|
45-60 minutes
|
Collaborators and Investigators
Investigators
- Principal Investigator: Flavio Hernández Castro, MD PhD, Hospital Universitario UANL
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GI18-0012
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gestational Diabetes
-
IRCCS Burlo GarofoloCompletedGestational Diabetes | Gestational Diabetes Mellitus | Pregnancy-Induced Diabetes | Diabetes Mellitus, Gestational | Diabetes, Pregnancy InducedIsrael, Italy, Netherlands, Slovenia, Sri Lanka
-
UPECLIN HC FM Botucatu UnespCompletedGestational Diabetes Mellitus | Pregestational Diabetes Mellitus | Mild Gestational HyperglycemiaBrazil
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University of Texas Southwestern Medical CenterCompletedMild Gestational DiabetesUnited States
-
Royal College of Surgeons, IrelandHealth Research Board, IrelandUnknownPre-Gestational Diabetes
-
University of Colorado, DenverKaiser PermanenteCompletedGestational Diabetes MellitusUnited States
-
Intermountain Health Care, Inc.Withdrawn
-
Baylor College of MedicineRecruitingGestational Diabetes MellitusUnited States
-
Joslin Diabetes CenterRoche DiagnosticsCompletedGestational Diabetes MellitusUnited States
-
Ludwig-Maximilians - University of MunichGerman Federal Ministry of Education and Research; Helmholtz Zentrum MünchenCompletedGestational Diabetes MellitusGermany
Clinical Trials on Fetal echocardiography
-
Assiut UniversityCompleted
-
Fundació Institut de Recerca de l'Hospital de la...UnknownFetal Cardiac Disorder
-
University of Wisconsin, MadisonNational Heart, Lung, and Blood Institute (NHLBI); Medical College of Wisconsin and other collaboratorsCompletedLong QT Syndrome | Fetal Arrhythmia | Abnormality in Fetal Heart Rate or RhythmUnited States
-
Baylor College of MedicineRecruiting
-
Grande International Hospital, NepalCompleted
-
Western Galilee Hospital-NahariyaNot yet recruitingPregnancy Related | Obesity, Morbid | Fetal Weight
-
University of California, San FranciscoCompletedAortic Stenosis | Hypoplastic Left Heart SyndromeUnited States
-
Rambam Health Care CampusTechnion, Israel Institute of TechnologyNot yet recruiting
-
Children's Hospital Medical Center, CincinnatiRecruitingCongenital Diaphragmatic Hernia | Pulmonary Hypoplasia | Pulmonary; HypertensionUnited States